Gilead Sciences holds the cleaner structural position, with the lead spread across stability and growth. Novo Nordisk A/S still has the edge on profitability, which keeps the comparison from looking entirely one-sided. On the market side, Gilead Sciences is in better shape — its trend is intact while Novo Nordisk A/S's trend has broken down. That puts structure and market broadly in agreement — Gilead Sciences's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels.
The clearest separation starts in stability, but growth adds another real layer to the result. Gilead Sciences, Inc. leads by 12 points on the overall comparison score.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. GILD and NOVO-B.CO share the same industry classification.
For a similarity-based comparison, see how Gilead Sciences and Novo Nordisk A/S each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
Gilead Sciences, Inc. is stronger, but the price setup still looks more supportive for Novo Nordisk A/S.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The stability gap is very wide, with the stronger side looking materially steadier through time.
Profitability still favours Novo Nordisk A/S, with a 7.2-point operating margin advantage keeping the comparison from looking fully resolved.
The lead is built on both stability and growth — though profitability still provides a counterweight.
Break down the GILD vs NOVO-B.CO comparison across all dimensions with the full interactive tool.
Explore how GILD and NOVO-B.CO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.